Clinical Trials Logo
  1. Home
  2. Amphetamine-related Disorders
  3. NCT00089440
  4. Details
NCT00089440 Clinical Trial

Assessment of Interactions Between Methamphetamine and Aripiprazole - 1

Amphetamine-Related Disorders Clinical Trial

Official title:
Assessment of Interactions Between IV Methamphetamine and Aripiprazole

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT00089440
Other study ID # NIDA-MDS-0002-1
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received August 5, 2004
Last updated January 10, 2017
Start date June 2004
Est. completion date March 2005

Study information
Verified date July 2005
Source National Institute on Drug Abuse (NIDA)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the interactions between intravenous methamphetamine and aripiprazole.

Description:

This is a double-blind, placebo-controlled human laboratory clinical pharmacology study to assess potential interactions between intravenous d-methamphetamine infusion and treatment with oral aripiprazole.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 17
Est. completion date March 2005
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Must meet DSM-4 criteria for methamphetamine abuse or dependence and are non-treatment seeking.

- Ability to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures.

Exclusion Criteria:

- Please contact the site for more information.

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Aripiprazole

Locations
Country Name City State
United States UCLA Integrated Substance Abuse Program Los Angeles California
United States New York University, School of Medicine New York New York

Sponsors (1)
Lead Sponsor Collaborator
National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Adverse effect measures
Primary pharmacokinetic assessment
See also
  Status Clinical Trial Phase
Completed NCT02232789 - Abuse Liability and Human Pharmacology of Mephedrone Phase 1
Completed NCT01449565 - Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM) Phase 2
Completed NCT00247572 - Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Phase 2
Active, not recruiting NCT00100074 - To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1 Phase 1
Active, not recruiting NCT00033072 - Assessment of Potential Interactions Between Methamphetamine and Selegiline - 1 Phase 1
Recruiting NCT06145698 - Treatment Effect of Cross-frequency Transcranial Alternating Current Stimulation on the MUD N/A
Completed NCT00990067 - Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) Phase 1
Completed NCT02797990 - Conflict Between Maternal Autonomy and Child Health in Substance-use N/A
Recruiting NCT01899313 - A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence N/A
Active, not recruiting NCT00265278 - Assessment of Interactions Between Intravenous Methamphetamine and Modafinil - 1 Phase 1
Active, not recruiting NCT00000350 - Effects of Stimulant Dependence on Human Striatal Dopamine System - 15 Phase 1
Active, not recruiting NCT00040040 - Assessment of Potential Interactions Between Methamphetamine and Bupropion - 1 Phase 1
Completed NCT00040053 - Ondansetron for the Treatment of Methamphetamine Dependence - 1 Phase 2
Completed NCT00895804 - Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine) Phase 1
Recruiting NCT03902405 - Computerized Exercise to Alter Stimulant Approach Responses N/A
Recruiting NCT04982796 - Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder Phase 1/Phase 2
Completed NCT01386177 - Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA) Phase 1
Completed NCT01136278 - Pharmacological Interaction Between Clonidine and Methylenedioxymethamphetamine (MDMA) Phase 1
Completed NCT00069251 - Bupropion for the Treatment of Methamphetamine Dependence - 1 Phase 2
Completed NCT01270672 - Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA) N/A